U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H27N
Molecular Weight 317.4672
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUTENAFINE

SMILES

CN(CC1=CC=C(C=C1)C(C)(C)C)CC2=C3C=CC=CC3=CC=C2

InChI

InChIKey=ABJKWBDEJIDSJZ-UHFFFAOYSA-N
InChI=1S/C23H27N/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20/h5-15H,16-17H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C23H27N
Molecular Weight 317.4672
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Butenafine is a synthetic antifungal agent that is structurally and pharmacologically related to allylamine antifungals. The exact mechanism of action has not been established, but it is suggested that butenafine's antifungal activity is exerted through the alteration of cellular membranes, which results in increased membrane permeability, and growth inhibition. Butenafine is mainly active against dermatophytes and has superior fungicidal activity against this group of fungi when compared to that of terbinafine, naftifine, tolnaftate, clotrimazole, and bifonazole. It is also active against Candida albicans and this activity is superior to that of terbinafine and naftifine. Butenafine also generates low MICs for Cryptococcus neoformans and Aspergillus spp. as well. Butenafine hydrochloride is marketed under the trade names Mentax, Butop (India) and is the active ingredient in Lotrimin Ultra. MENTAX Cream, 1%, is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (formerly Pityrosporum orbiculare). Although the mechanism of action has not been fully established, it has been suggested that butenafine, like allylamines, interferes with sterol biosynthesis (especially ergosterol) by inhibiting squalene monooxygenase, an enzyme responsible for converting squalene to 2,3-oxydo squalene. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Blockage of squalene monooxygenase also leads to a subsequent accumulation of squalene. When a high concentration of squalene is reached, it is thought to have an effect of directly kill fungal cells. Butenafine cream 1% is indicated in treatment of tinea pedis, tinea corporis and tinea cruris. In tinea pedis it is recommended twice daily for 7 days or once daily for 4 weeks. In tinea cruris and tinea corporis it is recommended once daily for two weeks.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MENTAX

Approved Use

MENTAX-TC Cream, 1%, is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (formerly Pityrosporum orbiculare).

Launch Date

1996
Primary
Butenafine

Approved Use

OTC labeling: Topical treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm)

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.4 ng/mL
6 g 1 times / day multiple, topical
dose: 6 g
route of administration: Topical
experiment type: MULTIPLE
co-administered:
BUTENAFINE blood
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
5 ng/mL
20 g 1 times / day multiple, topical
dose: 20 g
route of administration: Topical
experiment type: MULTIPLE
co-administered:
BUTENAFINE blood
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
23.9 ng × h/mL
6 g 1 times / day multiple, topical
dose: 6 g
route of administration: Topical
experiment type: MULTIPLE
co-administered:
BUTENAFINE blood
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
87.8 ng × h/mL
20 g 1 times / day multiple, topical
dose: 20 g
route of administration: Topical
experiment type: MULTIPLE
co-administered:
BUTENAFINE blood
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
35 h
20 g 1 times / day multiple, topical
dose: 20 g
route of administration: Topical
experiment type: MULTIPLE
co-administered:
BUTENAFINE blood
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1 % 1 times / day multiple, topical
Recommended
Dose: 1 %, 1 times / day
Route: topical
Route: multiple
Dose: 1 %, 1 times / day
Sources:
unhealthy, 2-12
Health Status: unhealthy
Age Group: 2-12
Sex: M+F
Sources:
PubMed

PubMed

TitleDatePubMed
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011-07-14
[Activity of butenafine against ocular pathogenic filamentous fungi in vitro].
2010-01
Simultaneous HPLC determination of butenafine hydrochloride and betamethasone in a cream formulation.
2009-09
Update on terbinafine with a focus on dermatophytoses.
2009-04-21
In vitro antifungal activities of luliconazole, a new topical imidazole.
2009
Fungal toenail infections.
2008-12-15
Are placebo-controlled trials of creams for athlete's foot still justified?
2008-09
Butenafine and superficial mycoses: current status.
2008-07
Randomised controlled trial of topical butenafine in tinea cruris and tinea corporis.
2007-07-24
Topical treatments for fungal infections of the skin and nails of the foot.
2007-07-18
An unprecedented rearrangement in collision-induced mass spectrometric fragmentation of protonated benzylamines.
2006-09
[The effect of propyl gallate on the activity of various antifungal drugs against filamentous fungi in vitro].
2006-04
What is the best way to treat tinea cruris?
2006-03
In vitro antifungal activity of ZJ-522, a new triazole restructured from fluconazole and butenafine, against clinically important fungi in comparison with fluconazole and butenafine.
2005-08
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005-06
Comparative efficacy of topical 1% butenafine and 1% clotrimazole in tinea cruris and tinea corporis: a randomized, double-blind trial.
2005
Topical therapy for fungal infections.
2004
Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria.
2003-09
Butenafine: an update of its use in superficial mycoses.
2002-09
A Japanese case of tinea corporis caused by Arthroderma benhamiae.
2002-04
KP-103, a novel triazole derivative, is effective in preventing relapse and successfully treating experimental interdigital tinea pedis and tinea corporis in guinea pigs.
2002
Six novel antimycotics.
2002
Experimental and conformational analyses of interactions between butenafine and lipids.
2001-12
Comparison of in vitro antifungal activities of topical antimycotics launched in 1990s in Japan.
2001-08
Efficacy and safety of butenafine in superficial dermatophytoses (tinea pedis, tinea cruris, tinea corporis).
2001-05
Butenafine hydrochloride (Mentax) cream for the treatment of hyperkeratotic type tinea pedis and its transfer into the horny layer, with or without concomitant application of 20% urea ointment (Keratinamin).
2001
Butenafine hydrochloride: for the treatment of interdigital tinea pedis.
2000-03
Butenafine, a fungicidal benzylamine derivative, used once daily for the treatment of interdigital tinea pedis.
1998-06
Butenafine.
1998-03
Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment.
1993-07-23
Two mechanisms of butenafine action in Candida albicans.
1993-04
[Synthesis and antifungal activity of butenafine hydrochloride (KP-363), a new benzylamine antifungal agent].
1991-02
Patents

Sample Use Guides

Patients with tinea (pityriasis) versicolor should apply MENTAX-TC Cream, 1% (Butenafine), once daily for seven days. Sufficient MENTAX-TC Cream, 1%, should be applied to cover affected areas and extending 4 inches (10.2 cm) onto normal skin immediately surrounding the affected area.
Route of Administration: Topical
Butenafine HCl shows minimum inhibitory concentrations ranging from 0.03–1.0 ug/mL against 30 isolates representing different dermatophyte species.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:07:43 GMT 2025
Edited
by admin
on Mon Mar 31 18:07:43 GMT 2025
Record UNII
91Y494NL0X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BUTENAFINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
BUTENAFINE [MI]
Preferred Name English
Butenafine [WHO-DD]
Common Name English
BUTENAFINE [VANDF]
Common Name English
butenafine [INN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000007566
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
WHO-ATC D01AE23
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
NDF-RT N0000175875
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
NDF-RT N0000007566
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
NCI_THESAURUS C514
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
WHO-VATC QD01AE23
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
Code System Code Type Description
CAS
101828-21-1
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY
DRUG CENTRAL
444
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY
MESH
C067594
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY
DAILYMED
91Y494NL0X
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY
WIKIPEDIA
BUTENAFINE
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY
EVMPD
SUB06012MIG
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY
EPA CompTox
DTXSID7040657
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY
MERCK INDEX
m2791
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY Merck Index
INN
6550
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY
CHEBI
3238
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY
LACTMED
Butenafine
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY
PUBCHEM
2484
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY
NCI_THESAURUS
C72959
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY
DRUG BANK
DB01091
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY
RXCUI
47461
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY RxNorm
SMS_ID
100000088608
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY
ChEMBL
CHEMBL990
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY
FDA UNII
91Y494NL0X
Created by admin on Mon Mar 31 18:07:43 GMT 2025 , Edited by admin on Mon Mar 31 18:07:43 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
MAJOR
PLASMA; URINE
Related Record Type Details
ACTIVE MOIETY